news
Gilead data lends insight into transforming HIV prevention landscape
Results suggest that the small molecule treatment could be an alternative to current medication that aims to prevent HIV infection and which require more frequent dosing.
List view / Grid view
tenofovir disoproxil fumarate (TDF)
news
Gilead small molecule demonstrates strong capability for HIV prevention
According to Gilead, the study is the first Phase III HIV prevention trial to demonstrate a zero-infection rate.
news
ViiV agrees to expand access to long-acting HIV PrEP
Under a new agreement, licenced manufacturers will be able to supply generic versions of ViiV’s long-acting cabotegravir HIV pre-exposure prophylaxis (PrEP) medication to developing nations.
news
Trial of new HIV PrEP medication stopped early due to effectiveness
The trial was stopped because the data suggested that injections of the long-acting antiretroviral drug cabotegravir (CAB LA) are highly effective for HIV pre-exposure prophylaxis (PrEP) in women.
news
Antiviral drug not beneficial for reducing mother-to-child transmission of hepatitis B
Tenofovir disoproxil fumarate (TDF) does not significantly reduce mother-to-child transmission of hepatitis B virus when taken during pregnancy and after delivery.
news
NIH begins large HIV treatment study in pregnant women
Clinical trial will compare three antiretroviral drug regimens...
